Product
Why ELNs and LIMS are not enough for PD teamsOne of the questions we’re asked frequently is whether Invert is an ELN or LIMS—our answer is that Invert captures both systems’ strengths and fixes their weaknesses. We’ll discuss the trade-offs and shortcomings of ELN and LIMS when it comes to bioprocess data to explain how.
With meta-learning techniques, Invert’s ML team was able to reduce new data needs by as much as 90% by leveraging old data from different, but loosely related, bioprocess programs.
.png)
Given the glaring challenge of managing bioprocess data, the question remains: Why have bioprocess data solutions been historically overlooked?
Suhas Guruprasad, the Head of AI at Invert, dives into the evolution of artificial intelligence, distinguishing between the actual capabilities of AI and the often exaggerated hype surrounding it.
.png)
Exciting news! Invert is launching a Q&A series, Pioneers in Bioprocessing, to chat with experts in bioprocessing and biotechnology to discuss their work, the potential of the bioeconomy at large, and the personal viewpoints of the individuals who make this work possible.
The transfer of institutional data and knowledge is critical to the development of biotechnologies, bioproducts, and biotherapeutics.
